170 related articles for article (PubMed ID: 33130928)
1. EZH2 inhibitory protein (EZHIP/Cxorf67) expression correlates strongly with H3K27me3 loss in posterior fossa ependymomas and is mutually exclusive with H3K27M mutations.
Nambirajan A; Sharma A; Rajeshwari M; Boorgula MT; Doddamani R; Garg A; Suri V; Sarkar C; Sharma MC
Brain Tumor Pathol; 2021 Jan; 38(1):30-40. PubMed ID: 33130928
[TBL] [Abstract][Full Text] [Related]
2. EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma.
Hübner JM; Müller T; Papageorgiou DN; Mauermann M; Krijgsveld J; Russell RB; Ellison DW; Pfister SM; Pajtler KW; Kool M
Neuro Oncol; 2019 Jul; 21(7):878-889. PubMed ID: 30923826
[TBL] [Abstract][Full Text] [Related]
3. EZHIP: a new piece of the puzzle towards understanding pediatric posterior fossa ependymoma.
Jenseit A; Camgöz A; Pfister SM; Kool M
Acta Neuropathol; 2022 Jan; 143(1):1-13. PubMed ID: 34762160
[TBL] [Abstract][Full Text] [Related]
4. Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas.
Pajtler KW; Wen J; Sill M; Lin T; Orisme W; Tang B; Hübner JM; Ramaswamy V; Jia S; Dalton JD; Haupfear K; Rogers HA; Punchihewa C; Lee R; Easton J; Wu G; Ritzmann TA; Chapman R; Chavez L; Boop FA; Klimo P; Sabin ND; Ogg R; Mack SC; Freibaum BD; Kim HJ; Witt H; Jones DTW; Vo B; Gajjar A; Pounds S; Onar-Thomas A; Roussel MF; Zhang J; Taylor JP; Merchant TE; Grundy R; Tatevossian RG; Taylor MD; Pfister SM; Korshunov A; Kool M; Ellison DW
Acta Neuropathol; 2018 Aug; 136(2):211-226. PubMed ID: 29909548
[TBL] [Abstract][Full Text] [Related]
5. Posterior fossa ependymoma H3 K27-mutant: an integrated radiological and histomolecular tumor analysis.
Mariet C; Castel D; Grill J; Saffroy R; Dangouloff-Ros V; Boddaert N; Llamas-Guttierrez F; Chappé C; Puget S; Hasty L; Chrétien F; Métais A; Varlet P; Tauziède-Espariat A
Acta Neuropathol Commun; 2022 Sep; 10(1):137. PubMed ID: 36104744
[TBL] [Abstract][Full Text] [Related]
6. PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism.
Jain SU; Do TJ; Lund PJ; Rashoff AQ; Diehl KL; Cieslik M; Bajic A; Juretic N; Deshmukh S; Venneti S; Muir TW; Garcia BA; Jabado N; Lewis PW
Nat Commun; 2019 May; 10(1):2146. PubMed ID: 31086175
[TBL] [Abstract][Full Text] [Related]
7. Common molecular features of H3K27M DMGs and PFA ependymomas map to hindbrain developmental pathways.
Pun M; Pratt D; Nano PR; Joshi PK; Jiang L; Englinger B; Rao A; Cieslik M; Chinnaiyan AM; Aldape K; Pfister S; Filbin MG; Bhaduri A; Venneti S
Acta Neuropathol Commun; 2023 Feb; 11(1):25. PubMed ID: 36759899
[TBL] [Abstract][Full Text] [Related]
8. Correction to: EZH2 inhibitory protein (EZHIP/Cxorf67) expression correlates strongly with H3K27me3 loss in posterior fossa ependymomas and is mutually exclusive with H3K27M mutations.
Nambirajan A; Sharma A; Rajeshwari M; Boorgula MT; Doddamani R; Garg A; Suri V; Sarkar C; Sharma MC
Brain Tumor Pathol; 2021 Apr; 38(2):145. PubMed ID: 33420598
[No Abstract] [Full Text] [Related]
9. Is H3K27me3 status really a strong prognostic indicator for pediatric posterior fossa ependymomas? A single surgeon, single center experience.
Tanrıkulu B; Danyeli AE; Özek MM
Childs Nerv Syst; 2020 May; 36(5):941-949. PubMed ID: 32025869
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome.
Panwalkar P; Clark J; Ramaswamy V; Hawes D; Yang F; Dunham C; Yip S; Hukin J; Sun Y; Schipper MJ; Chavez L; Margol A; Pekmezci M; Chung C; Banda A; Bayliss JM; Curry SJ; Santi M; Rodriguez FJ; Snuderl M; Karajannis MA; Saratsis AM; Horbinski CM; Carret AS; Wilson B; Johnston D; Lafay-Cousin L; Zelcer S; Eisenstat D; Silva M; Scheinemann K; Jabado N; McNeely PD; Kool M; Pfister SM; Taylor MD; Hawkins C; Korshunov A; Judkins AR; Venneti S
Acta Neuropathol; 2017 Nov; 134(5):705-714. PubMed ID: 28733933
[TBL] [Abstract][Full Text] [Related]
11. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
Araki A; Chocholous M; Gojo J; Dorfer C; Czech T; Heinzl H; Dieckmann K; Ambros IM; Ambros PF; Slavc I; Haberler C
Acta Neuropathol Commun; 2016 Aug; 4(1):88. PubMed ID: 27550150
[TBL] [Abstract][Full Text] [Related]
12. Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas.
Bayliss J; Mukherjee P; Lu C; Jain SU; Chung C; Martinez D; Sabari B; Margol AS; Panwalkar P; Parolia A; Pekmezci M; McEachin RC; Cieslik M; Tamrazi B; Garcia BA; La Rocca G; Santi M; Lewis PW; Hawkins C; Melnick A; David Allis C; Thompson CB; Chinnaiyan AM; Judkins AR; Venneti S
Sci Transl Med; 2016 Nov; 8(366):366ra161. PubMed ID: 27881822
[TBL] [Abstract][Full Text] [Related]
13. Molecular subtyping of ependymoma and prognostic impact of Ki-67.
Lim KY; Lee K; Shim Y; Park JW; Kim H; Kang J; Won JK; Kim SK; Phi JH; Park CK; Chung CK; Yun H; Park SH
Brain Tumor Pathol; 2022 Jan; 39(1):1-13. PubMed ID: 34812989
[TBL] [Abstract][Full Text] [Related]
14. H3 K27M and EZHIP Impede H3K27-Methylation Spreading by Inhibiting Allosterically Stimulated PRC2.
Jain SU; Rashoff AQ; Krabbenhoft SD; Hoelper D; Do TJ; Gibson TJ; Lundgren SM; Bondra ER; Deshmukh S; Harutyunyan AS; Juretic N; Jabado N; Harrison MM; Lewis PW
Mol Cell; 2020 Nov; 80(4):726-735.e7. PubMed ID: 33049227
[TBL] [Abstract][Full Text] [Related]
15. Targeting integrated epigenetic and metabolic pathways in lethal childhood PFA ependymomas.
Panwalkar P; Tamrazi B; Dang D; Chung C; Sweha S; Natarajan SK; Pun M; Bayliss J; Ogrodzinski MP; Pratt D; Mullan B; Hawes D; Yang F; Lu C; Sabari BR; Achreja A; Heon J; Animasahun O; Cieslik M; Dunham C; Yip S; Hukin J; Phillips JJ; Bornhorst M; Griesinger AM; Donson AM; Foreman NK; Garton HJL; Heth J; Muraszko K; Nazarian J; Koschmann C; Jiang L; Filbin MG; Nagrath D; Kool M; Korshunov A; Pfister SM; Gilbertson RJ; Allis CD; Chinnaiyan AM; Lunt SY; Blüml S; Judkins AR; Venneti S
Sci Transl Med; 2021 Oct; 13(614):eabc0497. PubMed ID: 34613815
[TBL] [Abstract][Full Text] [Related]
16. A coordinated approach for the assessment of molecular subgroups in pediatric ependymomas using low-cost methods.
de Sousa GR; Lira RCP; de Almeida Magalhães T; da Silva KR; Nagano LFP; Saggioro FP; Baroni M; Marie SKN; Oba-Shinjo SM; Brandelise S; de Paula Queiroz RG; Brassesco MS; Scrideli CA; Tone LG; Valera ET
J Mol Med (Berl); 2021 Aug; 99(8):1101-1113. PubMed ID: 33903940
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity within the PF-EPN-B ependymoma subgroup.
Cavalli FMG; Hübner JM; Sharma T; Luu B; Sill M; Zapotocky M; Mack SC; Witt H; Lin T; Shih DJH; Ho B; Santi M; Emery L; Hukin J; Dunham C; McLendon RE; Lipp ES; Gururangan S; Grossbach A; French P; Kros JM; van Veelen MC; Rao AAN; Giannini C; Leary S; Jung S; Faria CC; Mora J; Schüller U; Alonso MM; Chan JA; Klekner A; Chambless LB; Hwang EI; Massimino M; Eberhart CG; Karajannis MA; Lu B; Liau LM; Zollo M; Ferrucci V; Carlotti C; Tirapelli DPC; Tabori U; Bouffet E; Ryzhova M; Ellison DW; Merchant TE; Gilbert MR; Armstrong TS; Korshunov A; Pfister SM; Taylor MD; Aldape K; Pajtler KW; Kool M; Ramaswamy V
Acta Neuropathol; 2018 Aug; 136(2):227-237. PubMed ID: 30019219
[TBL] [Abstract][Full Text] [Related]
18. p16 Loss and E2F/cell cycle deregulation in infant posterior fossa ependymoma.
Lummus SC; Donson AM; Gowan K; Jones KL; Vibhakar R; Foreman NK; Kleinschmidt-DeMasters BK
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28548702
[TBL] [Abstract][Full Text] [Related]
19. Optimizing biomarkers for accurate ependymoma diagnosis, prognostication, and stratification within International Clinical Trials: A BIOMECA study.
Chapman RJ; Ghasemi DR; Andreiuolo F; Zschernack V; Espariat AT; Buttarelli FR; Giangaspero F; Grill J; Haberler C; Paine SML; Scott I; Jacques TS; Sill M; Pfister S; Kilday JP; Leblond P; Massimino M; Witt H; Modena P; Varlet P; Pietsch T; Grundy RG; Pajtler KW; Ritzmann TA
Neuro Oncol; 2023 Oct; 25(10):1871-1882. PubMed ID: 36916248
[TBL] [Abstract][Full Text] [Related]
20. Four methods to analyze H3K27M mutation in diffuse midline gliomas.
Zhao H; Fang X; Xue B
Pathol Res Pract; 2020 Sep; 216(9):153065. PubMed ID: 32825938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
